Αρχική World News Population Mortality from NSCLC in the US Fell Sharply Due to Treatment...

Population Mortality from NSCLC in the US Fell Sharply Due to Treatment Advances

A significant reduction in mortality from lung cancer in the US general population, mainly due to a rapid decline in mortality from non-small cell lung cancer (NSCLC) was reported on 13 August 2020 in The New England Journal of Medicine by Dr. Nadia Howlader of the Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute in Bethesda, MD, USA and colleagues. Population level mortality from NSCLC in the US fell sharply from 2013 to 2016, along with substantial improvement of survival after diagnosis. The analysis suggests that a reduction in incidence along with the treatment advances, in particular approval and use of targeted therapies during the study period is likely to explain the reduction in mortality observed.

The authors wrote in the study background that is important to assess trends in mortality from lung cancer according to subtype because the potential adoption of lung cancer screening coupled with reductions in smoking are likely to influence future mortality from lung cancer differentially according to histologic subtype.

Major improvements have been made in last years in NSCLC treatment with introduction in the practice of targeted therapies and immunotherapies. However, treatment for small cell lung cancer (SCLC) has shown limited improvements in efficacy in same timeframe.

To understand lung cancer mortality trends and the effect of preventive interventions as compared with treatment interventions, it is important to assess the individual contributions of NSCLC and SCLC to overall lung cancer incidence and mortality trends. Overall, mortality from lung cancer has been decreasing among men and women. However, this overall trend cannot be separated directly into subtype specific trends, because death certificates in the US do not record the cancer subtype.

To address this data limitation, the US Surveillance, Epidemiology, and End Results (SEER) Program has linked mortality records to incident cancer cases. In particular, the study team applied the incidence-based mortality method to SEER data to evaluate population level US mortality trends, according to sex, attributable to NSCLC and SCLC from 2001 through 2016. Since mortality captures the combined effects of lung cancer incidence and survival after diagnosis, they also assessed the contributions of lung cancer incidence and lung cancer specific survival to these trends. They also evaluated lung cancer incidence and survival according to cancer subtype, sex, and calendar year.

The study team found that mortality from NSCLC decreased even faster than the incidence of this subtype, and this decrease was associated with a substantial improvement in survival over time that corresponded to the timing of approval of targeted therapy.

Among men, incidence-based mortality from NSCLC decreased 6.3% annually from 2013 through 2016, whereas the incidence decreased 3.1% annually from 2008 through 2016. Corresponding lung cancer specific survival improved from 26% among men with NSCLC that was diagnosed in 2001 to 35% among those in whom it was diagnosed in 2014. This improvement in survival was found across all races and ethnic groups. Similar patterns were found among women with NSCLC.

However, mortality from SCLC declined almost entirely as a result of declining incidence, with no improvement in survival. This result correlates with limited treatment advances for SCLC in the timeframe of this study.

The authors concluded that they found a significant reduction in mortality from lung cancer in the US general population, mainly due to a rapid decline in mortality from NSCLC. They explained that the faster decreases in mortality from NSCLC as compared with the incidence of NSCLC are probably driven by improvements in survival, which are potentially driven by dissemination of targeted therapies for NSCLC. The survival benefit for patients with NSCLC treated with targeted therapy has been shown in clinical trials, but this study highlights their possible effect at the population level. The authors anticipate that incidence-based mortality methods will be valuable for evaluating trends in subtype specific mortality in the future, as additional new lung cancer treatments, as well as screening are penetrated in the population. 

Reference

Howlader N, Forjaz G, Mooradian MJ, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med 2020;383:640-9.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer

On 13 October 2021, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for...

From Scan to Scan: The Challenges of Living with Metastatic Cancer

October 15, 2021, by NCI Staff Bethany Ross has been living with metastatic neuroendocrine cancer since she was diagnosed in 2018. Credit: Used with permission from...

The award-winning researcher behind next generation sequencing

Next generation sequencing (NGS) has given the genomic research community ultra-high throughput, scalability, and speed that could only be dreamed of 20 years ago....

Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t Tell Their Doctors

Cancer and cancer treatment come with many side effects, including nausea, vomiting, and pain. In addition to the physical toll, the impacts to a...

Medicare Open Enrollment Starts Tomorrow!

Medicare open enrollment is upon us for 2022. If you are a Medicare recipient, this is the time of year when you can make...

Cancer in My Community: Providing Supportive Care in Serbia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...